Compound: FGI-106 free base
SMILES: n1c2c(c(NCCCN(C)C)cc1C)ccc3c2ccc4c3nc(cc4NCCCN(C)C)C
InChIKey: WJUPENLNVUCETH-UHFFFAOYSA-N
Synonyms: FGI-106 free base, 501081-38-5, NSC-306365, UNII-BRT994456W, BRT994456W, 1-N,7-N-bis[3-(dimethylamino)propyl]-3,9-dimethylquinolino[8,7-h]quinoline-1,7-diamine, Quino(8,7-H)quinoline-1,7-diamine, N1,N7-bis(3-(dimethylamino)propyl)-3,9-dimethyl-, Quino[8,7-h]quinoline-1,7-diamine, N1,N7-bis[3-(dimethylamino)propyl]-3,9-dimethyl-, orb1709702, CHEMBL1789789, SCHEMBL10005931, DTXSID701028028, AKOS040733158, DA-55873, HY-124618, CS-0087139, T11281, Q18354550, N,N'-bis-(3-dimethylamino-propyl)-3,9-dimethylquinolino[8,7-h]quinolin-1,7-diamine, N1,N7-bis[3-(dimethylamino)propyl]-3,9-dimethyl-quinolino[8,7-h]quinoline-1,7-diamine, N1,N1'-(3,9-Dimethylquinolino[8,7-h]quinoline-1,7-diyl)bis(N3,N3-dimethylpropane-1,3-diamine)
Theoretical properties:
molecular_formula: C28H38N6
molecular_weight: 458.6 g/mol
exact_mass: 458.31579524 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 2
hydrogen_bond_acceptor_count: 6
rotatable_bond_count: 10
heavy_atom_count: 34
topological_polar_surface_area: 56.3 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
{"pubchem": null, "chebi": null, "chembl": "Unnamed Compound is a small molecule listed in the ChEMBL database but has not progressed to an approved clinical phase.", "wikipedia": "Ebola, also known as Ebola virus disease (EVD) and Ebola hemorrhagic fever (EHF), is a zoonotic viral hemorrhagic fever in humans and other primates, caused by four of the six known ebolaviruses. Symptoms typically start anywhere between two days and three weeks after infection. The first symptoms are usually fever, sore throat, muscle pain, and headaches. These are usually followed by vomiting, diarrhoea, rash, hepatic and renal dysfunction, at which point some people begin to bleed both internally and externally. The disease causes a mortality rate of anywhere between 25 and 90%, averaging out at approximately 50%. The viral species involved and timing of treatment play a critical role in its prognosis. Death is often due to shock from fluid loss, and typically occurs between 6 and 16 days after the first symptoms appear.\nThe viruses have caused intermittent outbreaks in Sub-Sahara Africa since 1976 when the disease was first reported, with the largest one being the 2014 Western African epidemic. They spread through direct contact with body fluids, such as blood from infected humans or other animals, or from contact with items that have recently been contaminated with infected body fluids. There have been no documented cases, either in nature or under laboratory conditions, of spread through the air between humans or other primates. After recovering from Ebola, semen or breast milk may continue to carry the virus for anywhere between several weeks to several months. Fruit bats are believed to be the natural host of the viruses; they are able to spread the viruses without being affected by it. The symptoms of Ebola may resemble those of several other diseases, including malaria, cholera, typhoid fever, meningitis and other viral hemorrhagic fevers. Diagnosis is confirmed by testing blood samples for the presence of viral RNA, viral antibodies or the virus itself.\nControl of outbreaks requires coordinated medical services and community engagement, including rapid detection, contact tracing of those exposed, quick access to laboratory services, care for those infected, and proper disposal of the dead through cremation or burial. Prevention measures involve wearing proper protective clothing and washing hands when in close proximity to patients and while handling potentially infected bushmeat, as well as thoroughly cooking bushmeat. Two treatments (atoltivimab/maftivimab/odesivimab and ansuvimab) are associated with improved outcomes. Early supportive care and treatment of symptoms increases the survival rate considerably compared to late start. These include oral rehydration therapy (drinking slightly sweetened and salty water) or giving intravenous fluids, and treating symptoms. An Ebola vaccine was approved by the US FDA in December 2019. In October 2020, atoltivimab/maftivimab/odesivimab (Inmazeb) was approved for medical use in the United States to treat the disease caused by Zaire ebolavirus.\n\n"}